Edition:
United Kingdom

OncoTherapy Science Inc (4564.T)

4564.T on Tokyo Stock Exchange

235JPY
22 Nov 2017
Change (% chg)

¥1 (+0.43%)
Prev Close
¥234
Open
¥234
Day's High
¥236
Day's Low
¥233
Volume
560,700
Avg. Vol
671,955
52-wk High
¥315
52-wk Low
¥221

Latest Key Developments (Source: Significant Developments)

OncoTherapy Science receives patent in Japan
Thursday, 13 Jul 2017 

July 13 (Reuters) - OncoTherapy Science Inc <4564.T>:* Says it received a patent (No.6159948 )for MELK specific inhibitors in Japan.  Full Article

OncoTherapy Science says first-patient enrollment in Phase I/II clinical study of OTS167
Friday, 15 Jul 2016 

OncoTherapy Science Inc <4564.T>:Says the first patient has been enrolled in Phase I/II clinical study of OTS167, an MELK-specific inhibitor, for Acute Myeloid Leukemia.  Full Article

OncoTherapy Science gets patent license
Monday, 16 May 2016 

OncoTherapy Science Inc <4564.T>: Says received a patent license in China .Says the patent is for specific inhibitor of TOPK (T-LAK cell-originated protein kinase), which being developed as an anti-cancer agent.  Full Article

OncoTherapy Science announces trial result of phase I clinical study of the anti-cancer therapeutic antibody ‘OTSA101’ against synovial sarcoma
Tuesday, 22 Mar 2016 

OncoTherapy Science Inc:Announces the positive results of the primary objectives which were safety and bio-distribution were confirmed from Phase I clinical study of the anti-cancer therapeutic antibody ‘OTSA101’ against synovial sarcoma conducted in France.  Full Article

OncoTherapy Science announces positive trial result of phase I/II clinical study of OTSGC-A24
Tuesday, 22 Mar 2016 

OncoTherapy Science Inc:Announces positive trial result of phase I/II clinical study of carcinoma peptide vaccine cocktail OTSGC-A24 for the treatment of gastric cancer, in Singapore, Korea and Japan.  Full Article

OncoTherapy Science announces positive trial result of phase I clinical study of MELK inhibitor OTS167
Wednesday, 16 Mar 2016 

OncoTherapy Science Inc:Announces positive trial result of phase I clinical study of MELK inhibitor OTS167 in Australia.Says the clinical study turns out good oral absorption properties of OTS167.  Full Article

OncoTherapy Science announces completion of phase I clinical study of the anti-cancer therapeutic antibody ‘OTSA101’
Sunday, 21 Feb 2016 

OncoTherapy Science Inc:Says the phase I clinical study of the anti-cancer therapeutic antibody against synovial sarcoma ‘OTSA101’ has been completed.  Full Article

OncoTherapy Science to start Phase I/II clinical study of OTS167 in USA
Tuesday, 26 Jan 2016 

OncoTherapy Science Inc:Announces commencement of Phase I/II clinical study of OTS167, a MELK specific inhibitor, for Acute Myeloid Leukemia (AML) patients following the approval of the investigational new drug (IND) application by the US Food and Drug Administration (FDA).  Full Article

OncoTherapy Science MELK inhibitor, OTS167, Phase I/II clinical study commencement in U.S
Monday, 25 Jan 2016 

OncoTherapy Science Inc:Says FDA has approved the commencement of Phase I/II clinical study of MELK inhibitor, OTS167, for acute myeloid leukemia.  Full Article

OncoTherapy Science announces patent registration for TOPK-specific inhibitors in Japan
Sunday, 27 Dec 2015 

OncoTherapy Science Inc:Announces that OncoTherapy was approved a substance patent in Japan for the TOPK (T-LAK cell-originated protein kinase) -specific inhibitors that are being developed by OncoTherapy as anti-cancer drugs.Patent No. 5849302.  Full Article

BRIEF-OncoTherapy Science says close of peptide vaccine related agreement with ONO PHARMACEUTICAL

* Says peptide vaccine related agreement with ONO PHARMACEUTICAL CO., LTD. will close on Sept. 4